Enzyme company looks to maximize capacity, enhance efficiencies
More than GBP6 million (US$7.8 million) will be invested in total, comprising an 11,000 square foot extension to the existing building, which has just been completed. The next step is to outfit the building with cutting-edge equipment, including a 10 cubic foot fermenter and down-stream processing machinery. It will all be controlled by state-of-the-art software to maximize capacity and enhance efficiencies.
The new production area also offers future expansion capacity, negating the need for the company to move.
As well as the increased manufacturing capacity, Biocatalysts recently launched MetXtra, a unique enzyme discovery platform that provides a fast and cost-effective approach to novel enzyme development. Add into this mix the recent purchase of Biocatalysts by BRAIN AG, which further strengthens the company’s offering and gives customers access to an unparalleled range of capabilities in enzyme discovery.
Daren Bryce, commercial director at Biocatalysts, said: “This represents a very exciting time in the specialty enzyme field. The unique breadth of offering, from discovery right through to large scale production, that Biocatalysts has to offer will allow previously inaccessible novel enzymes at commercial scale to our customers.”